Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lexagene Holdings Inc. (V:LXG)

Business Focus: Bio Diagnostics & Testing

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LXG within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 16, 2021 07:45 ET
LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has entered into a Cooperative Research and Development...
Read full article
Sep 07, 2021 07:45 ET
LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial Samples Compared to Conventional Culture
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced it successfully utilized its MiQLab™...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.09
--
--
Price to Sales - TTM
807.98
--
10.38
Price to Book - most recent quarter
5.32
8.27
3.26
Price to Cash Flow per share - TTM
--
9.32
13.33
Price to Free Cash Flow per share - TTM
--
15.43
31.14
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 202131,123-20,358
Aug 15, 202151,481-111,651
Jul 31, 2021163,1328,344
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

LexaGene Holdings, Inc. is a Canada-based molecular diagnostics company. The Company develops genetic analyzers for pathogen detection and other molecular markers for on-site testing in veterinary diagnostics, food safety and for use in open-access markets, including clinical research, agricultural testing and biodefense. It offers MiQLab genetic analyzer. The MiQLab genetic analyzer offers automated pathogen detection and customized testing. The MiQLab genetic analyzer draws each liquid sample into a sample preparation cartridge, where microbes are concentrated and lysed before the genetic material is purified. Its analyzer pulls the purified genomic material from inside the cartridge into the system's microfluidics where a series of real-time polymerase chain reaction (PCR) mixtures are assembled, multiplex quantitative polymerase chain reactions (qPCR) are amplified and the results are analyzed.

See business summary

 

Twitter

Search (past week) for $LXG.CA LXG.V